#United States #Phoenix #cancer screening #TOBY Inc #MedTech Accelerator

TOBY's Milestone in Cancer Screening Technology

TOBY, Inc., a pioneering biotechnology firm, has recently announced a significant achievement—it has successfully completed its participation in the Mayo Clinic and Arizona State University (ASU) Alliance for Health Care MedTech Accelerator. This program, held in Phoenix, Arizona, is exclusively designed for early-stage medical technology companies striving to innovate within the healthcare landscape.

Among numerous applicants from across the globe, TOBY was selected as one of just ten companies to join the 2025 cohort, marking an essential step in the firm's mission to revolutionize early cancer detection. At the heart of TOBY's efforts is a cutting-edge non-invasive urine spectroscopy platform combined with advanced Artificial Intelligence (AI). This technology aims to facilitate accessible and cost-effective cancer screenings, presenting a novel avenue for healthcare professionals and patients alike.

As the global landscape of cancer incidences is projected to rise dramatically—from 2022 to 2045, according to the International Agency for Research on Cancer (IARC)—innovative solutions like those proposed by TOBY are critical. The National Cancer Institute estimates that in the United States alone, over two million individuals will be diagnosed with cancer by the year 2025. In this light, TOBY's mission becomes even more urgent and necessary. The company aims to support earlier detection of cancer when treatment is most effective.

Matthew Laskowski, CEO of TOBY, expressed the pressing need for affordable and accessible screening methods. He emphasized that participating in the MedTech Accelerator has been instrumental in advancing their technology and refining their overall development strategy. The MedTech Accelerator provides invaluable resources, including mentorship and guidance from seasoned professionals in the medical and technology fields, helping participants build a sustainable business model and effectively navigate the healthcare ecosystem.

In addition to supportive networks, the program offers TOBY direct access to various clinical, academic, and commercial resources that enhance their capacity for innovation. The company’s focus on utilizing machine learning technology for detecting molecular patterns associated with early-stage cancers underscores their commitment to addressing the real needs faced by patients and healthcare systems today.

Dragan Sebišanović, TOBY's Chief Science Officer, elaborated on the firm’s advanced technology, stating, "Our technology utilizes machine learning to help identify molecular signatures linked to early-stage cancer. By decoding these unique patterns, we can provide a reliable screening process that potentially detects multiple cancers through a simple urine test."

TOBY has emerged as a promising player in the biotechnology field by developing an innovative urine test capable of identifying ten types of cancer—a spectrum that represents over 60% of all new cancer cases diagnosed globally. This groundbreaking test combines the precision of spectroscopy with changes in biomarkers (volatile organic compounds) and sophisticated algorithms, ensuring early, user-friendly, and affordable cancer screenings for the population.

The undertaking showcases TOBY's commitment to making a meaningful impact in the healthcare sector by enhancing early detection methods. As they continue to progress with their technology, the company invites interested parties to learn more through their website, Toby.health.

TOBY, inspired by the determination and investigative spirit of Sherlock Holmes's Bloodhound, embodies a relentless pursuit of excellence and innovation in healthcare. The company's journey serves as a remarkable example of how biotechnology can be leveraged to confront and mitigate the challenges posed by rising global cancer incidences.

In summary, TOBY's successful completion of the MedTech Accelerator program not only marks a crucial milestone for the company but also symbolizes hope for improved cancer screening methods in the near future. As the healthcare landscape evolves, ventures like TOBY lead the charge towards a healthier, more accessible world for patients everywhere.